Variable-age epilepsy syndrome with developmental and/or epileptic encephalopathy or progressive neurological deterioration
MONDO:0800495An epilepsy syndrome characterized by seizures along with developmental and/or epileptic encephalopathy or progressive neurological deterioration where age at seizure onset varies.
Also known as: VAE-SDE/PND
21 clinical trials for this condition and its sub-types, 0 tagged with Variable-age epilepsy syndrome with developmental and/or epileptic encephalopathy or progressive neurological deterioration itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Variable-age epilepsy syndrome with developmental and/or epileptic encephalopathy or progressive neurological deterioration
-
Progressive myoclonus epilepsy 5 trials · 12 incl. sub-types
15 sub-types
- MERRF syndrome 5 trials
- Lafora disease 1 trial Sub-types →
- Unverricht-Lundborg syndrome 1 trial
- Neuronal ceroid lipofuscinosis 8 northern epilepsy variant 1 trial
- Action myoclonus-renal failure syndrome 0 trials
- Early-onset Lafora body disease 0 trials
- Epilepsy, progressive myoclonic, 11 0 trials
- Epilepsy, progressive myoclonic, 12 0 trials
- Epilepsy, progressive myoclonic, 1B 0 trials
- Familial encephalopathy with neuroserpin inclusion bodies 0 trials
- Progressive myoclonic epilepsy type 3 0 trials
- Progressive myoclonic epilepsy type 6 0 trials
- Progressive myoclonic epilepsy type 7 0 trials
- Progressive myoclonic epilepsy type 8 0 trials
- Progressive myoclonic epilepsy type 9 0 trials
-
Rasmussen subacute encephalitis 2 trials
Most studied deeper sub-types
-
Custom-Made genetic drug targets rare brain disease in first human test
Disease control OngoingThis study tests a personalized medicine called an antisense oligonucleotide, designed specifically for one person with dentatorubral-pallidoluysian atrophy (DRPLA), a rare genetic brain disorder. The treatment aims to reduce seizures and improve quality of life by targeting the …
Phase 1/2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Real-World study tracks Epidyolex's Long-Term impact on seizures
Disease control OngoingThis study follows 158 people in France who are prescribed Epidyolex (a cannabidiol-based medicine) for seizures as part of their normal care. Researchers will track how long people stay on the treatment, side effects, seizure frequency, and changes in daily functioning and quali…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Custom drug targets rare genetic brain disease in First-Ever human test
Disease control OngoingThis study tests a custom-made drug called an antisense oligonucleotide (ASO) designed for one person with dentatorubral-pallidoluysian atrophy (DRPLA), a rare genetic disorder that affects movement and brain function. The drug aims to reduce the harmful effects of the mutated AT…
Phase 1/2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
One-of-a-Kind drug trial targets rare genetic brain disease
Disease control OngoingThis study tests a custom-made genetic medicine (called an antisense oligonucleotide) designed for one person with dentatorubral-pallidoluysian atrophy (DRPLA), a rare inherited brain disorder. The treatment aims to reduce seizures and improve quality of life. Only one participan…
Phase 1/2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could a stem cell transplant stop the immune system from attacking the brain?
Disease control OngoingThis phase 2 trial tests whether high-dose chemotherapy followed by a stem cell transplant can stop the immune system from attacking the nervous system in people with autoimmune neurologic diseases like multiple sclerosis and stiff person syndrome. The treatment aims to weaken th…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New inhaler aims to stop prolonged seizures fast and safely
Symptom relief By invitation onlyThis study tests the long-term safety of an inhaled medication called Staccato alprazolam for people aged 12 and older who have prolonged seizures. About 300 participants will use the inhaler when a seizure starts to see if it stops the seizure quickly and without serious side ef…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC